Table 1 Patient clinical data, feasible HLA-I information, neo- and viral peptides library size and no. of T cell responses for all patients. No. of T cell responses indicated for each patient at respective timepoints.

From: Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma

Patient

Clinical data

Feasible HLA-I

HLA-I-feasible neopeptides

Viral peptides

T cell neoepitope responses, per time point

Outcome (Best RECIST 1.1)

HLA-A

HLA-B

HLA-C

Predicted (EL%Rank <0.5)

Library size

Library size

Pre-treatment

3 weeks

9 weeks

20-29 weeks

49-73 weeks

156-166 weeks

231+ weeks

#40

PD2

A0201/A3201

B1801

C0401/C0701

576

576

9

5

–

–

–

–

–

–

#9723

PD2

A0101/A2402

B0702/B0801

C0701/C0702

16

200

16

1

–

–

–

–

–

–

#1249

PD2

A0301/A6801

B3501/B4402

C0401/C0501

177

200

12

1

2

–

–

–

–

–

#2937

PD

A3201

B1801/B3503

C0401

322

322

1

9

5

–

–

–

–

–

#1994

SD

A0301

B0702

C0702

56

200

9

3

2

3

–

–

–

–

#5221

PD

A2402/A3001

B5701

C0602

150

200

6

2

3

2

–

–

–

–

#6428

PD

A2601

B2705

C0202

18

200

1

0

0

0

–

–

–

–

#7577

PD

A0101/A0201

B5101

C0602/C0701

35

200

14

1

2

0

–

–

–

–

#8728

PD

–

B4403/B5101

–

14

200

4

5

2

0

–

–

–

–

#471

PD

A0201/A6801

B3503/B5101

C0401

155

200

11

0

0

0

–

–

–

–

#3529

PD

A0205/A2402

–

C0602

92

200

5

5

3

7

–

–

–

–

#5338

PD

A0201/A2402

B4001/B4002

C0202/C0304

44

200

16

1

0

0

–

–

–

–

#2849

PD

A0201/A0301

B0702/B2705

C0702

420

420

17

5

1

2

–

–

–

–

#7729

PD

A0101/A0301

B0801/B1302

C0602/C0701

75

200

15

5

3

5

3

–

–

–

#9517

SD

A0101/A0301

B3501/B3801

C0401

254

254

13

2

7

1

4

–

–

–

#1849

SD

A0101/A1101

–

C0401/C0602

136

200

7

10

9

14

–

–

–

–

#68001

SD

A0301

B1501

C0401

214

214

10

0

5

1

–

–

–

–

#6229

CR

A3001/A3201

B1302

C0401/C0602

250

250

4

5

13

3

–

2

–

–

#5037

CR

A2601

B3801/B4002

C0202

587

587

2

2

6

4

–

2

0

0

#2389

CR

A0101/A2402

B3801/B4001

C0304

203

203

9

2

4

3

–

0

0

1

#2131

CR

A0201

B0801

C0202/C0701

411

411

14

0

4

1

–

6

5

4

#2278

CR

A0201/A2402

–

C0202

52

200

13

1

2

1

–

3

1

1

#1233

PR

A1101/A2601

B2705/B3501

C0202/C0702

26

200

8

0

0

2

–

–

1

0

#5122

PR

A2402/A3201

B3801

–

140

200

4

1

0

0

–

–

0

0

  1. A dash (–) indicates no sample screening at the given time point. Clinical outcome determined from Best RECIST 1.1 criteria during therapy. 1TCRb analysis for tumor not performed due to failed sequencing quality control. 2Patient only scanned at baseline. Source data are provided as a Source Data file.
Back to article page